一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Dapagliflozin: A Review in Type 2 Diabetes.

Published:1 July 2019 DOI: 10.1007/s40265-019-01148-3 PMID: 31236801
Sohita Dhillon

Abstract

Dapagliflozin (Forxiga?) is a highly potent, reversible and selective sodium-glucose cotransporter-2 inhibitor indicated worldwide for the treatment of type 2 diabetes (T2D). In the EU, oral dapagliflozin once daily is approved for use as monotherapy (in patients who are intolerant of metformin) and as add-on combination therapy (with other glucose-lowering agents, including insulin) for T2D when diet and exercise alone do not provide adequate glycaemic control. In numerous well-designed clinical studies and their extensions, dapagliflozin as monotherapy and combination therapy with other antihyperglycaemic agents provided effective glycaemic control and reduced bodyweight and blood pressure (BP) across a broad spectrum of patients. Dapagliflozin reduced the rate of cardiovascular (CV) death or hospitalization for heart failure (HHF), did not adversely affect major adverse CV events (MACE) and possibly reduced progression of renal disease relative to placebo in patients with established atherosclerotic CV disease (CVD) or multiple risk factors for CVD. Dapagliflozin was generally well tolerated, with a low risk of hypoglycaemia; diabetic ketoacidosis (DKA), although rare, and genital infections were more common with dapagliflozin than placebo. Given its antihyperglycaemic, cardioprotective and possibly renoprotective properties and generally favourable tolerability profile, dapagliflozin provides an important option for the management of a broad patient population, regardless of the history of CVD.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Dapagliflozin 461432-26-8 C21H25ClO6 828 suppliers $5.00-$1504.50
Dapagliflozin propanediol monohydrate 960404-48-2 C24H33ClO8 330 suppliers Inquiry

Similar articles

IF:13

Dapagliflozin: a review of its use in type 2 diabetes mellitus.

Drugs Greg L Plosker,etc Published: 3 December 2012
IF:13

Linagliptin: in type 2 diabetes mellitus.

Drugs Lesley J Scott,etc Published: 26 March 2011
IF:2.5

Efficacy of voglibose in type 2 diabetes.

Expert Opinion on Pharmacotherapy Kohei Kaku,etc Published: 1 June 2014
芦山县| 平昌县| 襄汾县| 阿坝县| 永平县| 永平县| 宜章县| 岑巩县| 汨罗市| 黔江区| 平阴县| 天津市| 厦门市| 永胜县| 西盟| 淳安县| 克拉玛依市| 山东省| 张掖市| 铜鼓县| 铜梁县| 宝坻区| 金昌市| 和龙市| 彭水| 翼城县| 东丽区| 精河县| 塔城市| 泽库县| 河池市| 宜春市| 大悟县| 阿城市| 高清| 美姑县| 安图县| 灵武市| 扬州市| 大同市| 田阳县|